U
Aeolus Pharmaceuticals, Inc.
AOLS
$0.0001
$0.000.00%
E
Sell
4/26/2018Downgrade
Aeolus Pharmaceuticals, Inc. (AOLS) was downgraded to E+ from D- on 4/26/2018 due to a decline in the volatility index and total return index.
Aeolus Pharmaceuticals, Inc. (AOLS) was downgraded to E+ from D- on 4/26/2018 due to a decline in the volatility index and total return index.
D
Sell
4/9/2018Upgraded
Aeolus Pharmaceuticals, Inc. (AOLS) was upgraded to D- from E+ on 4/9/2018 due to a significant increase in the valuation index.
Aeolus Pharmaceuticals, Inc. (AOLS) was upgraded to D- from E+ on 4/9/2018 due to a significant increase in the valuation index.
E
Sell
2/23/2018Downgrade
Aeolus Pharmaceuticals, Inc. (AOLS) was downgraded to E+ from D- on 2/23/2018 due to a decline in the total return index and volatility index.
Aeolus Pharmaceuticals, Inc. (AOLS) was downgraded to E+ from D- on 2/23/2018 due to a decline in the total return index and volatility index.
D
Sell
2/6/2018Upgraded
Aeolus Pharmaceuticals, Inc. (AOLS) was upgraded to D- from E+ on 2/6/2018 due to an increase in the total return index, valuation index and volatility index.
Aeolus Pharmaceuticals, Inc. (AOLS) was upgraded to D- from E+ on 2/6/2018 due to an increase in the total return index, valuation index and volatility index.
E
Sell
1/2/2018Downgrade
Aeolus Pharmaceuticals, Inc. (AOLS) was downgraded to E+ from D- on 1/2/2018 due to a decline in the total return index and volatility index.
Aeolus Pharmaceuticals, Inc. (AOLS) was downgraded to E+ from D- on 1/2/2018 due to a decline in the total return index and volatility index.
D
Sell
11/27/2017Upgraded
Aeolus Pharmaceuticals, Inc. (AOLS) was upgraded to D- from E+ on 11/27/2017 due to an increase in the growth index. Operating cash flow increased 36.76% from -$914 to -$578, and EBIT increased 8.31% from -$1.04M to -$949.
Aeolus Pharmaceuticals, Inc. (AOLS) was upgraded to D- from E+ on 11/27/2017 due to an increase in the growth index. Operating cash flow increased 36.76% from -$914 to -$578, and EBIT increased 8.31% from -$1.04M to -$949.
E
Sell
6/1/2017Downgrade
Aeolus Pharmaceuticals, Inc. (AOLS) was downgraded to E+ from D- on 6/1/2017 due to a decline in the total return index and volatility index.
Aeolus Pharmaceuticals, Inc. (AOLS) was downgraded to E+ from D- on 6/1/2017 due to a decline in the total return index and volatility index.
D
Sell
5/17/2017Upgraded
Aeolus Pharmaceuticals, Inc. (AOLS) was upgraded to D- from E+ on 5/17/2017 due to an increase in the growth index. Total revenue increased 55.42% from $83 to $129, operating cash flow increased 27.46% from -$1.26M to -$914, and EBIT increased 4.78% from -$1.09M to -$1.04M.
Aeolus Pharmaceuticals, Inc. (AOLS) was upgraded to D- from E+ on 5/17/2017 due to an increase in the growth index. Total revenue increased 55.42% from $83 to $129, operating cash flow increased 27.46% from -$1.26M to -$914, and EBIT increased 4.78% from -$1.09M to -$1.04M.
E
Sell
4/7/2017Downgrade
Aeolus Pharmaceuticals, Inc. (AOLS) was downgraded to E+ from D- on 4/7/2017 due to a decline in the efficiency index, volatility index and growth index. Operating cash flow declined 109.65% from -$601 to -$1.26M, total revenue declined 84.8% from $546 to $83, and total capital declined 33.18% from $3.2M to $2.14M.
Aeolus Pharmaceuticals, Inc. (AOLS) was downgraded to E+ from D- on 4/7/2017 due to a decline in the efficiency index, volatility index and growth index. Operating cash flow declined 109.65% from -$601 to -$1.26M, total revenue declined 84.8% from $546 to $83, and total capital declined 33.18% from $3.2M to $2.14M.
D
Sell
11/7/2016Downgrade
Aeolus Pharmaceuticals Inc. (AOLS) was downgraded to D- from D on 11/7/2016 due to a decline in the total return index and volatility index.
Aeolus Pharmaceuticals Inc. (AOLS) was downgraded to D- from D on 11/7/2016 due to a decline in the total return index and volatility index.
D
Sell
8/16/2016Upgraded
Aeolus Pharmaceuticals Inc. (AOLS) was upgraded to D from D- on 8/16/2016 due to a noticeable increase in the efficiency index, growth index and total return index. Earnings per share increased from -$0.02 to -$0.01, operating cash flow increased 19.47% from -$935 to -$753, and total revenue increased 16.81% from $565 to $660.
Aeolus Pharmaceuticals Inc. (AOLS) was upgraded to D from D- on 8/16/2016 due to a noticeable increase in the efficiency index, growth index and total return index. Earnings per share increased from -$0.02 to -$0.01, operating cash flow increased 19.47% from -$935 to -$753, and total revenue increased 16.81% from $565 to $660.
D
Sell
8/8/2016Upgraded
Aeolus Pharmaceuticals Inc. (AOLS) was upgraded to D- from E+ on 8/8/2016 due to an increase in the volatility index and total return index.
Aeolus Pharmaceuticals Inc. (AOLS) was upgraded to D- from E+ on 8/8/2016 due to an increase in the volatility index and total return index.
E
Sell
5/17/2016Downgrade
Aeolus Pharmaceuticals Inc. (AOLS) was downgraded to E+ from D- on 5/17/2016 due to a decline in the volatility index, growth index and total return index. Earnings per share declined from -$0.0116 to -$0.02, and operating cash flow declined 14.02% from -$820 to -$935.
Aeolus Pharmaceuticals Inc. (AOLS) was downgraded to E+ from D- on 5/17/2016 due to a decline in the volatility index, growth index and total return index. Earnings per share declined from -$0.0116 to -$0.02, and operating cash flow declined 14.02% from -$820 to -$935.
D
Sell
3/11/2016Downgrade
Aeolus Pharmaceuticals Inc. (AOLS) was downgraded to D- from D on 3/11/2016 due to a major decline in the volatility index, total return index and efficiency index. Net income declined 138.02% from -$434 to -$1.03M.
Aeolus Pharmaceuticals Inc. (AOLS) was downgraded to D- from D on 3/11/2016 due to a major decline in the volatility index, total return index and efficiency index. Net income declined 138.02% from -$434 to -$1.03M.
D
Sell
1/12/2016Downgrade
Aeolus Pharmaceuticals Inc. (AOLS) was downgraded to D from D+ on 1/12/2016 due to a decline in the total return index and valuation index.
Aeolus Pharmaceuticals Inc. (AOLS) was downgraded to D from D+ on 1/12/2016 due to a decline in the total return index and valuation index.
D
Sell
12/28/2015Upgraded
Aeolus Pharmaceuticals Inc. (AOLS) was upgraded to D+ from D on 12/28/2015 due to an increase in the growth index and total return index. Total revenue increased 1,382.54% from $63 to $934.
Aeolus Pharmaceuticals Inc. (AOLS) was upgraded to D+ from D on 12/28/2015 due to an increase in the growth index and total return index. Total revenue increased 1,382.54% from $63 to $934.
D
Sell
9/16/2015Downgrade
Aeolus Pharmaceuticals Inc. (AOLS) was downgraded to D from D+ on 9/16/2015 due to a noticeable decline in the growth index, total return index and solvency index. Operating cash flow declined 174.37% from -$199 to $148, total revenue declined 94.7% from $1.19M to $63, and the quick ratio declined from 1.13 to 0.72.
Aeolus Pharmaceuticals Inc. (AOLS) was downgraded to D from D+ on 9/16/2015 due to a noticeable decline in the growth index, total return index and solvency index. Operating cash flow declined 174.37% from -$199 to $148, total revenue declined 94.7% from $1.19M to $63, and the quick ratio declined from 1.13 to 0.72.
D
Sell
4/15/2015Upgraded
Aeolus Pharmaceuticals Inc. (AOLS) was upgraded to D+ from D on 4/15/2015 due to an increase in the solvency index.
Aeolus Pharmaceuticals Inc. (AOLS) was upgraded to D+ from D on 4/15/2015 due to an increase in the solvency index.
D
Sell
8/15/2014Downgrade
Aeolus Pharmaceuticals Inc. (AOLS) was downgraded to D from D+ on 8/15/2014 due to a decline in the efficiency index and valuation index. Net income declined 460.64% from -$437 to $1.58M.
Aeolus Pharmaceuticals Inc. (AOLS) was downgraded to D from D+ on 8/15/2014 due to a decline in the efficiency index and valuation index. Net income declined 460.64% from -$437 to $1.58M.
D
Sell
5/28/2014Upgraded
Aeolus Pharmaceuticals Inc. (AOLS) was upgraded to D+ from D on 5/28/2014 due to an increase in the efficiency index, growth index and volatility index. Total revenue increased 81.34% from $793 to $1.44M.
Aeolus Pharmaceuticals Inc. (AOLS) was upgraded to D+ from D on 5/28/2014 due to an increase in the efficiency index, growth index and volatility index. Total revenue increased 81.34% from $793 to $1.44M.
OTC PK
04/02/2025 9:31AM Eastern
Quotes delayed
